Theriva Biologics, Inc. — 10-Q Summary
Issuer clarification: The supplied filing is for Synthetic Biologics, Inc. (formerly Adeona Pharmaceuticals, Inc.), not Theriva Biologics, Inc. It covers the quarter ended March 31, 2012; the financial statements are unaudited.
Business context and reporting period
The company was shifting its focus toward synthetic biology and drug development. Its pipeline included a preclinical DNA-based pulmonary arterial hypertension (PAH) candidate partnered with Intrexon; Phase II Trimesta (oral estriol) trials for relapsing-remitting multiple sclerosis and MS-related cognitive dysfunction; Effirma (flupirtine) for fibromyalgia, partnered with Meda AB; and AEN-100 (zinc acetate) for ALS, in trial preparation. On March 8, 2012, the company sold its Adeona Clinical Laboratory business and classified it as discontinued operations.
Financial performance and liquidity
- Revenue: No continuing-operations revenue was reported. Laboratory fees of $115,000 in Q1 2012, versus $323,000 in Q1 2011, were reported in discontinued operations.
- Expenses and loss: Continuing operating expenses were $1.854 million, up from $1.464 million. General and administrative expense was $1.468 million (up about 19%); research and development was $386,000 (up about 67%). Continuing-operations net loss was $1.849 million, or $0.06 per share, versus $2.223 million, or $0.09 per share.
- Net result: A $677,000 gain on the laboratory sale contributed to $649,000 of discontinued-operations income. Consolidated net loss was $1.200 million, or $0.04 per share, compared with a $2.186 million loss, or $0.09 per share, in Q1 2011. The year-over-year improvement reflects discontinued-operations sale proceeds and the absence of 2011 warrant-related expense; it does not indicate operating profitability.
- Cash flow: Net cash used in operating activities was $1.415 million, versus $281,000 in Q1 2011. Financing provided $1.539 million, mainly from $1.471 million of warrant exercises and $68,000 of option exercises. Cash increased $124,000 to $6.802 million; management reported approximately $6.5 million at April 30, 2012.
- Liquidity and balance sheet: Current assets were $7.325 million and current liabilities $443,000 at March 31, 2012. Total liabilities were $443,000, with no debt reported. Equity was $7.906 million and accumulated deficit $53.073 million. Assets included a $700,000, two-year non-recourse note receivable bearing 5.7% interest, due March 1, 2014, secured by the laboratory's assets.
- Margins: Continuing revenue was zero, so a meaningful continuing-operations margin is not presented. Laboratory discontinued-operations results were a $28,000 loss before the sale gain.
- Share-based compensation and dilution: Stock-based compensation expense was $508,000. The company granted 1.3 million options during the quarter, with stated grant-date fair value of approximately $3 million. Weighted-average shares outstanding rose to 32.0 million from 25.2 million in Q1 2011.
Material changes versus the prior comparable period
- Operating expenses increased, particularly R&D, which management attributed to pipeline expansion and initiation of preclinical and clinical programs.
- Operating cash use increased to $1.415 million from $281,000. The company continued to depend on financing rather than product revenue.
- The laboratory sale generated a $677,000 gain and removed the business from continuing operations; the sale consideration included assigned receivables and the $700,000 note.
- Q1 2011 included $759,000 of net other expense, including warrant-related charges; Q1 2012 reported $5,000 of other income.
Outlook, commentary, risks, and unusual items
- Management said cash on hand was expected to fund planned operating needs for at least the next 12 months, but emphasized that this estimate depends on assumptions and that there were no committed financing sources. Additional capital may be needed and could dilute shareholders; failure to raise funds could delay or curtail development.
- Development remains early-stage and dependent on clinical outcomes, regulatory approvals, grants, partners, and third parties. Trimesta's 164-patient relapsing-remitting MS trial had completed enrollment and was expected to continue dosing and monitoring for two years; management said existing grant funding should cover it through completion. The cognitive-dysfunction trial was enrolling. AEN-100 required a planned Phase I study before the planned ALS trial; the company committed approximately $400,000 toward the first phase.
- Meda AB was responsible for future Effirma development costs. The company could receive further milestones and royalties only if development and commercialization succeed; no royalty revenue had been received to date.
- Auditor issue: After quarter-end, the company disclosed that the PCAOB had commented that the partner who issued the 2011 audit opinion was not authorized under partner-rotation rules. The company reported an updated audit opinion in its May 11, 2012 Form 10-K/A and sought SEC guidance. It said it would not issue shares under Form S-3 registration statements pending guidance and intended to return funds received from warrant holders. The filing does not clearly reconcile this statement with Q1 warrant-exercise proceeds.
- Other key risks included the unproven nature of DNA-based therapeutics, clinical and manufacturing uncertainty, reliance on Intrexon and investigator-led programs, competition, limited intellectual-property protection for some candidates, and possible share dilution. The company reported effective disclosure controls and no material change in internal control during the quarter. Legal proceedings: none reported.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Synthetic Biologics, Inc., not Theriva Biologics, Inc.
- Check subsequent SEC filings for resolution of the auditor partner-rotation issue, the status of Form S-3 eligibility, and the disposition of warrant-exercise funds.
- Assess whether the stated 12-month cash runway remains adequate given operating cash use, expected development spending, and the lack of committed financing.
- Track trial progress, funding and partner responsibilities for each pipeline program, especially AEN-100's prerequisite Phase I study and the grant-supported Trimesta trials.
- Review potential dilution from outstanding options and warrants, recent option grants, and future capital-raising needs.